Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324621 · ClinicalTrials.gov registry record · Phase 1
Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02324621: Completed Phase 1 study of Unspecified Adult Solid Tumor, sponsored by Rutgers, The State University of New Jersey.
NCT02324621 is a Phase 1 study of Unspecified Adult Solid Tumor that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 26 participants, below the 36-participant average among 3 other Unspecified Adult Solid Tumor trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02324621, a Phase 1 study of Unspecified Adult Solid Tumor, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the long-term side effects of the continuation of oral ONC201 in treating patients with solid tumors that have spread to other places in the body who have previously benefited from receiving this drug. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
An adverse experience is defined as any unintended or abnormal clinical observation that is not of benefit to the patient. Either the condition was not present prior to exposure to the study therapy, or it has worsened in intensity or frequency following exposure to the study therapy. Descriptive statistics will be provided.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG Oral ONC201
Study Locations (1)
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-02-20 |
| Est. Completion | 2018-10-23 |
| Phase | Phase 1 |
What the finished NCT02324621 record still lists
NCT02324621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 36-participant average among 3 other Unspecified Adult Solid Tumor trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Unspecified Adult Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02324621 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02324621 about?
NCT02324621 is a clinical study titled "Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors". This phase I trial studies the long-term side effects of the continuation of oral ONC201 in treating patients with solid tumors that have spread to other places in the body who have previously benefited from receiving this drug. Oral ONC201 may stop the growth of tumor cells by blocking some of the ...
What is the current status of trial NCT02324621?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2015-02-20. Estimated completion is 2018-10-23.
What conditions does trial NCT02324621 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor.
What interventions are being tested in trial NCT02324621?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), Oral ONC201 (DRUG).
Who is sponsoring clinical trial NCT02324621?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02324621 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI